Generic Medicine Info
Indications and Dosage
Gastric ulcer, Gastritis
Adult: 100 mg tid, usually in the morning, evening and before bedtime.
May be taken with or without food.
Special Precautions
Elderly. Pregnancy and lactation.
Adverse Reactions
Significant: Dizziness, drowsiness, thrombocytopenia, leucopenia, hypersensitivity and anaphylactoid reactions (e.g. hives, rash, itching, eczema), shock, jaundice. Rarely, liver dysfunction.
Gastrointestinal disorders: Constipation, dry mouth, diarrhoea, nausea, vomiting, heartburn, abdominal pain, belching, sensation of abdominal enlargement, taste abnormality.
Investigations: Increased AST, ALT, alkaline phosphatase, or BUN levels.
Patient Counseling Information
This drug may cause drowsiness or dizziness, if affected, do not drive or operate machinery.
Mechanism of Action: Rebamipide is postulated to increase prostaglandin E2 in gastric mucosa and elevate gastric mucous, gastric mucosal blood flow and secretion of gastric alkaline. It also stimulates gastric mucosal cell growth and decreases gastric mucosa injury.
Absorption: Time to peak plasma concentration: 2 hours.
Distribution: Plasma protein binding: 98.4-98.6%.
Excretion: Via urine (approx 10% as unchanged drug).
Chemical Structure

Chemical Structure Image

Source: National Center for Biotechnology Information. PubChem Compound Summary for CID 5042, Rebamipide. Accessed Apr. 28, 2021.

Store below 30°C.
MIMS Class
Antacids, Antireflux Agents & Antiulcerants
ATC Classification
A02BX14 - rebamipide ; Belongs to the class of other drugs used in the treatment of peptic ulcer and gastro-oesophageal reflux disease (GERD).
Anon. Rebamipide. Lexicomp Online. Hudson, Ohio. Wolters Kluwer Clinical Drug Information, Inc. Accessed 05/04/2021.

Buckingham R (ed). Rebamipide. Martindale: The Complete Drug Reference [online]. London. Pharmaceutical Press. Accessed 05/04/2021.

Mucopro 100 mg Tablet (Kaufmann Pharma Inc.). MIMS Philippines. Accessed 05/04/2021.

Mucosta Tablets 100 (A. Menarini Singapore Pte Ltd). National Pharmaceutical Regulatory Agency - Ministry of Health Malaysia. Accessed 05/04/2021.

Disclaimer: This information is independently developed by MIMS based on Rebamipide from various references and is provided for your reference only. Therapeutic uses, prescribing information and product availability may vary between countries. Please refer to MIMS Product Monographs for specific and locally approved prescribing information. Although great effort has been made to ensure content accuracy, MIMS shall not be held responsible or liable for any claims or damages arising from the use or misuse of the information contained herein, its contents or omissions, or otherwise. Copyright © 2024 MIMS. All rights reserved. Powered by
Register or sign in to continue
Asia's one-stop resource for medical news, clinical reference and education
Already a member? Sign in
Register or sign in to continue
Asia's one-stop resource for medical news, clinical reference and education
Already a member? Sign in